These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25326927)

  • 1. Effect of management strategies and clinical status on costs of care for advanced HIV.
    Barnett PG; Chow A; Joyce VR; Bayoumi AM; Griffin SC; Sun H; Holodniy M; Brown ST; Cameron W; Sculpher M; Youle M; Anis AH; Owens DK
    Am J Manag Care; 2014 May; 20(5):e129-37. PubMed ID: 25326927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.
    Keiser P; Nassar N; Kvanli MB; Turner D; Smith JW; Skiest D
    J Acquir Immune Defic Syndr; 2001 May; 27(1):14-9. PubMed ID: 11404515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated direct costs of medical care for HIV-infected patients within a regional population from 2006 to 2017.
    Krentz HB; Vu Q; Gill MJ
    HIV Med; 2020 May; 21(5):289-298. PubMed ID: 31852032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
    Krentz HB; Gill MJ
    HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and resource use of patients on antiretroviral therapy in the urban and semiurban public sectors of South Africa.
    Meyer-Rath G; Miners A; Santos AC; Variava E; Venter WD
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):e25-32. PubMed ID: 22895437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
    Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
    Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
    Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies.
    Kimaro GD; Mfinanga S; Simms V; Kivuyo S; Bottomley C; Hawkins N; Harrison TS; Jaffar S; Guinness L;
    PLoS One; 2017; 12(2):e0171917. PubMed ID: 28234969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costing analysis of national HIV treatment and care program in Vietnam.
    Duong AT; Kato M; Bales S; Do NT; Minh Nguyen TT; Thanh Cao TT; Nguyen LT
    J Acquir Immune Defic Syndr; 2014 Jan; 65(1):e1-7. PubMed ID: 23846564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
    Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic Review.
    Ward T; Sugrue D; Hayward O; McEwan P; Anderson SJ; Lopes S; Punekar Y; Oglesby A
    J Manag Care Spec Pharm; 2020 Feb; 26(2):104-116. PubMed ID: 32011956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France.
    Colin X; Lafuma A; Costagliola D; Lang JM; Guillon P
    Pharmacoeconomics; 2010; 28 Suppl 1():59-68. PubMed ID: 21182344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis.
    Leisegang R; Cleary S; Hislop M; Davidse A; Regensberg L; Little F; Maartens G
    PLoS Med; 2009 Dec; 6(12):e1000189. PubMed ID: 19956658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre.
    Beck EJ; Mandalia S; Griffith R; Beecham J; Walters MD; Boulton M; Miller DL
    Pharmacoeconomics; 2000 Jan; 17(1):53-69. PubMed ID: 10747765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary costs of HIV healthcare in the HAART era.
    Gebo KA; Fleishman JA; Conviser R; Hellinger J; Hellinger FJ; Josephs JS; Keiser P; Gaist P; Moore RD;
    AIDS; 2010 Nov; 24(17):2705-15. PubMed ID: 20859193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
    Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
    Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.